Biblio
Export 1161 results:
Author Title [ Type] Year Filters: First Letter Of Last Name is W [Clear All Filters]
“Can Diet Supplements of Macular Pigment of Lutein, Zeaxanthin, and Meso-zeaxanthin Affect Cognition?”, J Alzheimers Dis, vol. 87, no. 3, pp. 1079-1087, 2022.
, “Capsaicin Attenuates Amyloid-β-Induced Synapse Loss and Cognitive Impairments in Mice.”, J Alzheimers Dis, vol. 59, no. 2, pp. 683-694, 2017.
, “"Captive by the Uncertainty"-Experiences with Anticipatory Guidance for People Living with Dementia and Their Caregivers at a Specialty Dementia Clinic.”, J Alzheimers Dis, vol. 86, no. 2, pp. 787-800, 2022.
, “Cardiorespiratory Fitness and White Matter Neuronal Fiber Integrity in Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 61, no. 2, pp. 729-739, 2018.
, “Central Olfactory Dysfunction in Alzheimer's Disease and Mild Cognitive Impairment: A Functional MRI Study.”, J Alzheimers Dis, vol. 59, no. 1, pp. 359-368, 2017.
, “Cerebral Amyloid Angiopathy and Cerebral Amyloid Angiopathy-Related Inflammation: Comparison of Hemorrhagic and DWI MRI Features.”, J Alzheimers Dis, vol. 64, no. 4, pp. 1113-1121, 2018.
, “Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimer's Disease.”, J Alzheimers Dis, vol. 62, no. 4, pp. 1815-1826, 2018.
, “Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimer's Disease.”, J Alzheimers Dis, vol. 62, no. 4, pp. 1815-1826, 2018.
, “Cerebral Artery Pulsatility is Associated with Cognitive Impairment and Predicts Dementia in Individuals with Subjective Memory Decline or Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 60, no. 2, pp. 625-632, 2017.
, “Cerebral Glucose Metabolism is Associated with Verbal but not Visual Memory Performance in Community-Dwelling Older Adults.”, J Alzheimers Dis, vol. 52, no. 2, pp. 661-72, 2016.
, “Cerebral Small Vessel Disease and Motoric Cognitive Risk Syndrome: Results from the Kerala-Einstein Study.”, J Alzheimers Dis, vol. 50, no. 3, pp. 699-707, 2016.
, “Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort.”, J Alzheimers Dis, vol. 54, no. 1, pp. 287-95, 2016.
, “Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Cerebral Amyloid Angiopathy-Related Inflammation.”, J Alzheimers Dis, vol. 50, no. 3, pp. 759-64, 2016.
, “Cerebrospinal Fluid Amyloid-β Levels are Increased in Patients with Insomnia.”, J Alzheimers Dis, vol. 61, no. 2, pp. 645-651, 2018.
, “Cerebrospinal Fluid Amyloid-β Levels are Increased in Patients with Insomnia.”, J Alzheimers Dis, vol. 61, no. 2, pp. 645-651, 2018.
, “The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting.”, J Alzheimers Dis, vol. 60, no. 2, pp. 561-576, 2017.
, “Cerebrospinal Fluid Aβ42/Aβ40 as a Means to Limiting Tube- and Storage-Dependent Pre-Analytical Variability in Clinical Setting.”, J Alzheimers Dis, vol. 57, no. 2, pp. 437-445, 2017.
, “Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 58, no. 3, pp. 939-950, 2017.
, “Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 58, no. 3, pp. 939-950, 2017.
, “Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 58, no. 3, pp. 939-950, 2017.
, “Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team.”, J Alzheimers Dis, vol. 55, no. 1, pp. 19-35, 2017.
, “Cerebrospinal Fluid Biomarkers for the Differential Diagnosis between Alzheimer's Disease and Frontotemporal Lobar Degeneration: Systematic Review, HSROC Analysis, and Confounding Factors.”, J Alzheimers Dis, vol. 55, no. 2, pp. 625-644, 2017.
, “Cerebrospinal Fluid Biomarkers for the Differential Diagnosis between Alzheimer's Disease and Frontotemporal Lobar Degeneration: Systematic Review, HSROC Analysis, and Confounding Factors.”, J Alzheimers Dis, vol. 55, no. 2, pp. 625-644, 2017.
, “Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years.”, J Alzheimers Dis, vol. 49, no. 3, pp. 733-41, 2016.
, “Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.”, Arch Gen Psychiatry, vol. 69, no. 1, pp. 98-106, 2012.
,